Nov-DB2 is under clinical development by NovMetaPharma and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nov-DB2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nov-DB2 overview

NovDB-2 is under development for the treatment of type 2 diabetes and obesity. It acts by targeting insulin-degrading enzyme (IDE). The drug candidate is a new chemical entity.

NovMetaPharma overview

NovMetaPharma develops and distributes dietary products and novel drugs for the treatment of metabolic diseases. The company is investigating its lead pipeline candidate, Cyclo-Z, for the treatment of type 2 diabetes, and obesity; and another pipeline candidate for the treatment of Alzheimer’s disease. The company develops and distributes healthy dietary products. The company also collaborates with research institutes for advancing its therapeutic agents in the areas of metabolic diseases, diseases of immune system, osteoporosis, and non-alcoholic fatty liver. It has partnerships with CRO cooperation, POSTECH, and Department of Veterans Affairs (US). Novmetapharma is headquartered in Gangnam-gu, Seoul, Korea.

For a complete picture of Nov-DB2’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.